Shares of Ambrx Biopharma Inc. (NYSE:AMAM – Get Free Report) have received a consensus rating of “Moderate Buy” from the eight research firms that are covering the company, MarketBeat.com reports. Four investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $24.13.
Several brokerages recently issued reports on AMAM. Robert W. Baird reissued a “neutral” rating and set a $28.00 target price on shares of Ambrx Biopharma in a report on Tuesday, January 16th. Cantor Fitzgerald reissued an “overweight” rating on shares of Ambrx Biopharma in a report on Friday, January 12th. B. Riley cut shares of Ambrx Biopharma from a “buy” rating to a “neutral” rating and raised their target price for the stock from $26.00 to $28.00 in a report on Tuesday, January 9th. Finally, JMP Securities reissued a “market perform” rating on shares of Ambrx Biopharma in a report on Wednesday, January 10th.
Check Out Our Latest Report on Ambrx Biopharma
Hedge Funds Weigh In On Ambrx Biopharma
Ambrx Biopharma Stock Up 0.1 %
Shares of NYSE:AMAM opened at $28.00 on Tuesday. The stock’s 50-day moving average price is $27.83 and its 200-day moving average price is $17.30. Ambrx Biopharma has a 12-month low of $6.55 and a 12-month high of $28.15.
About Ambrx Biopharma
Ambrx Biopharma Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2.
Read More
- Five stocks we like better than Ambrx Biopharma
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- MarketBeat Week in Review – 3/11 – 3/15
- What Is WallStreetBets and What Stocks Are They Targeting?
- Why Dollar General and Dollar Tree Are Similar Yet Different
- Are Penny Stocks a Good Fit for Your Portfolio?
- Jabil Stock Implodes: Market Manufactures Entry for New Money
Receive News & Ratings for Ambrx Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ambrx Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.